NCT01011972已完成1 期
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 4
- 主要终点
- The primary objective of this study is to determine the maximum tolerated dose of XMT-1107 when given via IV once every three weeks.
研究概览
简要总结
XMT-1107 has been shown in nonclinical studies to slow the growth of tumors. These effects may result from blocking the growth of new blood vessels that help the tumors survive.
详细描述
This is an open-label, ascending-dose study of XMT-1107 administered intravenously over 90 minutes every 21 days (1 cycle). Blood sampling for PK analyses will be performed immediately prior to dosing and after dosing. Adverse events will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria (CTC) version 4.0 (CTCAE v4.0)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have a histological diagnosis of advanced solid tumor and must be refractory to standard therapy or have no effective therapy.
- •Measurable or evaluable disease.
- •At least 42 days since administration of mitomycin or nitrosoureas and 28 days since any other chemotherapy, investigational agent, and/or radiation therapy.
- •Age ≥ 18 years old.
- •Have the following laboratory values:
- •Absolute neutrophil count (ANC) ≥ 1500 cells/mm3
- •Platelet count ≥ 100,000 cells/mm3
- •Hemoglobin ≥ 9 g/dL
- •Serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min (Calculated by Cockroft and Gault method. Creatinine clearance (mL/min) = (140-age) x weight (kg)/72 x (serum creatinine in mg/dL) = ml**/min (**for females, multiply results by 0.85))
- •Total bilirubin ≤ 1.5 mg/dL or ≤ upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the institutional upper limit of normal (ULN) or ≤ 5 times ULN of liver metastases are present
- •Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5 times the ULN
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-
- •Life expectancy of at least 3 months.
- •Signed informed written consent.
排除标准
- •Known brain metastases (either currently or previously).
- •Peripheral neuropathy ≥ Grade
- •Ataxia ≥ Grade
- •Cognitive disturbance ≥ Grade
- •History of seizures.
- •Patients known to be human immunodeficiency virus (HIV) positive.
- •Active infections requiring IV antibiotics or serious intercurrent illness, including hepatitis B or C.
- •Unstable angina, recent myocardial infarction (within the previous 6 months), or use of ongoing maintenance therapy for life-threatening arrhythmia.
- •Known hypersensitivity to this class of drugs.
- •Pregnant or nursing women, women who are of childbearing potential and are not using an effective method of either barrier or hormonal contraceptives. Men who are not using an effective method of barrier contraceptive, or who would not be willing to continue to use these effective methods for the duration of the study.
- •Patients who have had a major surgical procedure (not including mediastinoscopy), open biopsy, or significant traumatic injury ≤ 4 weeks prior to beginning treatment.
- •Patients with proteinuria at screening as demonstrated by either:
- •urine protein creatinine (UPC) ratio ≥ 1.0 at screening OR
- •urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection, and must demonstrate ≤ 1 g of protein/24 hours to be eligible)
- •Patients with a serious non-healing wound, active ulcer, or untreated bone fracture.
- •Patients with history of hematemesis or hemoptysis (defined as having bright red blood of ½ teaspoon or more per episode) ≤ 1 month prior to study enrollment.
- •Inadequately controlled hypertension (defined as systolic blood pressure >140 mm Hg and/or diastolic blood pressure > 90 mm Hg while on antihypertensive medications). Initiation of antihypertensive agents is permitted provided adequate control is documented at least 1 week prior to beginning study treatment.
- •Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis) ≤ 6 months prior to Day 1 of treatment.
- •History of stroke or transient ischemic attack ≤ 6 months prior to beginning treatment.
- •Any prior history of hypertensive crisis or hypertensive encephalopathy.
- •History of abdominal fistula or gastrointestinal perforation ≤ 6 months prior to Day 1 of beginning treatment.
- •QTc interval > 470 milliseconds as calculated by Bazett's formula.
- •Any issue that, in the opinion of the Investigator, would render the patient unsuitable for study participation.
研究组 & 干预措施
XMT-1107
Experimental
Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m^2, doubling in dose to 24 mg/m^2, then 40 mg/m^2, then 60 mg/m^2, then 80 mg/m^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
干预措施: XMT-1107 (Drug)
结局指标
主要结局
The primary objective of this study is to determine the maximum tolerated dose of XMT-1107 when given via IV once every three weeks.
时间窗: Adverse events are assessed during each treatment cycle.
次要结局
- Assess the safety of XMT-1107.(Throughout Cycle 1)
- Observe for evidence of anti-tumor activity by XMT-1107.(Course of study)
- Monitor the effect of XMT-1107 on MetAP2 inhibition in leukocytes from patients(Cycle 1 and Cycle 2)
- Assess the pharmacokinetics (PK) of XMT-1107 and its release product(Samples for PK are collected during Cycle 1 and prior to each subsequent treatment cycle)
- Determine the recommended Phase 2 dose of XMT-1107(Throughout Cycle 1)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic AdenocarcinomaAdvanced Pancreatic CancerMetastatic Pancreatic CancerPancreatic AdenocarcinomaNCT01764477Prism Pharma Co., Ltd.20
已完成
2 期
GW572016 to Treat Recurrent Malignant Brain TumorsGliosarcomaGliomaGlioblastoma MultiformeBrain TumorGBMGSNCT00107003National Cancer Institute (NCI)9
已完成
1 期
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple MyelomaMultiple MyelomaNCT00346255ImmunoGen, Inc.37
已完成
1 期
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.Solid TumorsNCT02598960Bristol-Myers Squibb295
进行中（未招募）
1 期
Selinexor in the treatment of patients with Refractory and/or Relapsed Richter's TransformatioEUCTR2014-001240-38-GBKaryopharm Therapeutics Inc.50